Moreover, Han et al. proposed a biomarker panel comprising CA125, HE4, IL-6, and E-CAD that can distinguish between early-stage ovarian cancer patients and noncancer controls with a specificity of 95–100% [71]. Here, WFDC2 is linked to ovarian cancer.